← All candidates
Two insider buys in the last year — $111.0K in all.
37 filings on record.
ALZNAlzamend Neuro, Inc.
NasdaqCM · Healthcare · $8.83M
$1.83
+2.81% · Sep 16
Two insider buys in the last year — $111.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 sell
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 1 move explained
Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what ALZN ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$8.83M
Float
4.8M
99% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Ault Milton C III
Bought $108.9K on Apr 14 — 108,388 sh @ $1.00, held indirect, 93% of their stake.
3 of 4 positions beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
32 more transactions on Pro →Context
Wall St
$26.00 avg target
+1320.8% vs today · 1 analyst
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
The file stays open
37 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice